Publications
Detailed Information
Alterations in PD-L1 expression associated with acquisition of resistance to ALK inhibitors in ALK-rearranged lung cancer
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Su-Jung | - |
dc.contributor.author | Kim, Soyeon | - |
dc.contributor.author | Kim, Dong-Wan | - |
dc.contributor.author | Kim, Miso | - |
dc.contributor.author | Keam, Bhumsuk | - |
dc.contributor.author | Kim, Tae Min | - |
dc.contributor.author | Lee, Yusoo | - |
dc.contributor.author | Koh, Jaemoon | - |
dc.contributor.author | Jeon, Yoon Kyung | - |
dc.contributor.author | Heo, Dae Seog | - |
dc.date.accessioned | 2020-04-27T11:00:10Z | - |
dc.date.available | 2020-04-27T11:00:10Z | - |
dc.date.created | 2019-09-26 | - |
dc.date.issued | 2019-07 | - |
dc.identifier.citation | Cancer Research and Treatment, Vol.51 No.3, pp.1231-1240 | - |
dc.identifier.issn | 1598-2998 | - |
dc.identifier.other | 84552 | - |
dc.identifier.uri | https://hdl.handle.net/10371/165220 | - |
dc.description.abstract | Purpose The purpose of this study was to evaluate the relationships between the resistance of anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) to ALK inhibitors and the programmed cell death-1/programmed cell death-ligand 1 (PD-L1) pathway, we evaluated alterations in PD-L1 following acquisition of resistance to ALK inhibitors in ALK-positive lung cancer. Materials and Methods We established ALK inhibitor-resistant cell lines (H3122CR1, LR1, and CH1) by exposing the parental H3122 ALK-translocated NSCLC cell line to ALK inhibitors. Then, the double-resistant cell lines H3122CR1LR1 and CR1CH1 were developed by exposing the H3122CR1 to other ALK inhibitors. We compared the alterations in PD-L1 expression levels using western blotting, flow cytometry, and quantitative polymerase chain reaction. We also investigated gene expression using RNA sequencing. The expression of PD-L1 in the tumors from 26 ALK-positive metastatic NSCLC patients (11 ALK inhibitor-naive and 15 ALK inhibitor-resistant patients) was assessed by immunohistochemistry and analyzed. Results PD-L1 was expressed at higher levels in ALK inhibitor-resistant cell lines than in the ALK inhibitor-naive parental cell line at the total protein, surface protein, and mRNA levels. Furthermore, PD-L1 expression in the double-resistant cell lines was much higher than that in the single resistant cell lines. RNA sequencing demonstrated that expression of immune-related genes were largely involved in ALK inhibitor resistance. The mean value of the PD-L1 H-score was 6.5 pre-treatment and 35.0 post-treatment, and the fold difference was 5.42 (p=0.163). Conclusion PD-L1 expression increased following acquisition of ALK inhibitor resistance in ALK-positive NSCLC cell lines and tumors. | - |
dc.language | 영어 | - |
dc.publisher | 대한암학회 | - |
dc.title | Alterations in PD-L1 expression associated with acquisition of resistance to ALK inhibitors in ALK-rearranged lung cancer | - |
dc.type | Article | - |
dc.contributor.AlternativeAuthor | 전윤경 | - |
dc.contributor.AlternativeAuthor | 김동완 | - |
dc.contributor.AlternativeAuthor | 허대석 | - |
dc.identifier.doi | 10.4143/crt.2018.486 | - |
dc.citation.journaltitle | Cancer Research and Treatment | - |
dc.identifier.wosid | 000476707300038 | - |
dc.identifier.scopusid | 2-s2.0-85065901781 | - |
dc.citation.endpage | 1240 | - |
dc.citation.number | 3 | - |
dc.citation.startpage | 1231 | - |
dc.citation.volume | 51 | - |
dc.identifier.sci | 000476707300038 | - |
dc.identifier.kciid | ART002486745 | - |
dc.description.isOpenAccess | Y | - |
dc.contributor.affiliatedAuthor | Kim, Dong-Wan | - |
dc.contributor.affiliatedAuthor | Jeon, Yoon Kyung | - |
dc.contributor.affiliatedAuthor | Heo, Dae Seog | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.subject.keywordPlus | EGFR MUTATIONS | - |
dc.subject.keywordPlus | MAPK | - |
dc.subject.keywordPlus | GENE | - |
dc.subject.keywordPlus | ACTIVATION | - |
dc.subject.keywordPlus | DOCETAXEL | - |
dc.subject.keywordPlus | NIVOLUMAB | - |
dc.subject.keywordPlus | PATHWAYS | - |
dc.subject.keywordPlus | BRAF | - |
dc.subject.keywordPlus | MEK | - |
dc.subject.keywordAuthor | Anaplastic lymphoma kinase | - |
dc.subject.keywordAuthor | Lung neoplasms | - |
dc.subject.keywordAuthor | Drug resistance | - |
dc.subject.keywordAuthor | B7-H1 antigen | - |
- Appears in Collections:
- Files in This Item:
Item View & Download Count
Items in S-Space are protected by copyright, with all rights reserved, unless otherwise indicated.